N-Power Medicine and VieCure Partner to Transform Clinical Trial Access in Community Oncology
核心洞察
N-Power Medicine (搜索) and VieCure (搜索) have announced a strategic partnership to integrate precision medicine insights and clinical trial access directly into community oncology (搜索) practices through their combined platforms.
The collaboration addresses a critical gap where fewer than 5% of adult cancer (搜索) patients participate in clinical trials, despite 85% receiving care in community settings.
The partnership combines N-Power's Kaleido Registry (搜索) with VieCure (搜索)'s Halo Intelligence Platform (搜索) to create an AI-enabled ecosystem that captures clinical trial-grade data at the point of care.
N-Power Medicine (搜索) and VieCure (搜索) have announced a strategic partnership designed to revolutionize precision medicine delivery and clinical trial access in community oncology (搜索) settings. The collaboration integrates N-Power's proprietary Kaleido Registry (搜索) with VieCure's Halo Intelligence Platform (搜索), creating an AI-enabled ecosystem that brings cutting-edge research capabilities directly to the point of care.
Addressing Critical Access Barriers
The partnership tackles a fundamental challenge in cancer (搜索) drug development: the severe underrepresentation of patients in clinical trials. Currently, fewer than 5% of adult cancer patients participate in clinical trials, primarily due to limited access in community settings where 85% of patients receive their care. This disparity creates a significant bottleneck in drug development and limits patient access to potentially life-saving treatments.
"This partnership represents a fundamental shift in how we approach clinical trial access and precision medicine in community oncology (搜索)," said Michael Power, CEO of VieCure (搜索). "With N-Power's real-time prospective data approach and the Halo Intelligence platform (搜索), we're not just improving trial matching, we're creating a seamless workflow that transforms every patient encounter into an opportunity for precision medicine and clinical research participation."
Technology Integration and Capabilities
N-Power's Kaleido Registry (搜索) represents a first-of-its-kind, AI-enabled, human-in-the-loop data engine that prospectively captures clinical trial-grade data at the point of care, before treatment decisions are made. This system operates as an always-on Prospective External Control Arm (ProECA) platform, enabling more sophisticated trial designs that can move beyond traditional randomized clinical trials.
Through the partnership, community oncologists in the VieCure (搜索) network will access real-time clinical trial opportunities and precision medicine insights directly within their existing workflows. The integration provides oncologists with immediate recommendations for both treatment optimization and clinical trial eligibility at the moment of care decision-making.
VieCure (搜索)'s Halo Intelligence Platform (搜索) serves as the first AI-enabled clinical decision support and smart electronic medical record platform designed specifically for community oncology (搜索). The platform assists clinicians in managing personalized treatment plans throughout cancer (搜索) diagnosis, therapy, and follow-up care across VieCure's network of more than 100 community cancer center locations.
Clinical Impact and Drug Development Acceleration
The collaboration creates a powerful infrastructure for accelerating drug development timelines while broadening access to clinical trials in community settings. By enabling drug developers to utilize more sophisticated trial designs with embedded external control arms, the partnership aims to bring transformative therapies to patients faster.
"Strengthening the culture of research in community oncology (搜索) requires people, strategies to improve clinical efficiency, and technology," said Michael Seiden, MD, PhD, Chief Medical Officer of N-Power Medicine (搜索). "The complementarity between VieCure (搜索)'s Halo Intelligence platform (搜索) and N-Power's human-in-the-loop Kaleido Registry (搜索) infrastructure creates an ideal opportunity to unlock the potential of community oncology to play a major role in accelerating drug development and expanding patients' access to novel therapies."
Transforming Community Oncology Research
The partnership positions community oncology (搜索) practices as active participants in the evolution of personalized cancer (搜索) care and therapeutic advancement. By integrating research capabilities into routine care workflows, the collaboration aims to transform every patient encounter into a potential opportunity for precision medicine application and clinical research participation.
This model addresses the traditional barriers that have prevented community practices from participating meaningfully in clinical research, including resource constraints, workflow disruptions, and limited access to cutting-edge diagnostic and treatment matching technologies. The seamless integration of research capabilities into existing care delivery systems represents a significant advancement in making precision medicine accessible to the broader patient population receiving care in community settings.